Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 462.50
High: 462.50
Low: 462.50
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update & notice of results

25 Jul 2011 07:00

RNS Number : 9317K
Tristel PLC
25 July 2011
 



 

TRISTEL plc

("Tristel" or the "Company")

 

Trading update and results date

 

Tristel plc (AIM: TSTL), the manufacturer of infection control, contamination control and hygiene products, provides a trading update ahead of the publication of its preliminary results for the year to 30 June 2011.

 

Since the Licence Delays and Trading Update announcement of 28 April 2011, Tristel has now secured the licence to sell the Stella decontamination system in China and the VAH listing for the Wipes System in Germany.

 

In the final quarter of the financial year, ended 30 June 2011, sales in Germany have increased significantly each month in percentage terms and sales of the Crystel products, sold into the pharmaceutical and personal care market, have commenced. In June 2011, 30 Stella System upgrades were also sold to our Chinese distributor network.

 

The Board is pleased to report that it now anticipates pre-tax profit (before share based payments) will be greater than £500,000, exceeding its expectations at the time of the April announcement. The Company continues to pursue its expansion plan and remains debt free.

 

A preliminary announcement of results for the year ended 30 June 2011 will be made on Monday 24 October 2011.

 

For further information, please contact:

 

Tristel PLC

Paul Swinney, Chief Executive

Tel: 01638 721 500

paulswinney@tristel.com

Liz Dixon, Finance Director

Tel: 01638 721 500

lizdixon@tristel.com

Walbrook PR Ltd

Tel: 020 7933 8780

Fiona Henson

Mob: 07886 335 992 fiona.henson@walbrookpr.com

Helen Westaway

Mob: 07841 917 679 helen.westaway@walbrookpr.com

finnCap

Geoff Nash (Corporate Finance)

Tel: 020 7600 1658

Charlotte Stranner (Corporate Finance)

Tel: 020 7600 1658

Simon Starr (Corporate Broking)

Tel: 020 7220 0516

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTELLFLFDFBBBE
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.